Skip to main content
. 2015 Nov 19;20(2):316–328. doi: 10.1002/ejp.731

Table 2.

Treatment‐emergent adverse events (SAS)

Capsaicin 8% patch (= 282) Pregabalin (= 277)
Patients with TEAEs (n, %) 210 (74.5) 177 (63.9)
Patients with drug‐related TEAEs (n, %) 173 (61.3) 151 (54.5)
Days free from TEAEs (%, SD) 84.3 ± 26.5 64.5 ± 39.5
Days free from drug‐related TEAEs (%, SD) 94.5 ± 15.8 70.4 ± 37.9

SAS: Safety analysis set; SD: Standard deviation; TEAEs: Treatment‐emergent adverse events.